Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma

References

• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911.
   PubMed Web of Science ®Google Scholar
• The Japan Glaucoma Society Guidelines for Glaucoma (4th ed). Nippon Ganka Gakkai Zasshi. 2018;122(1):5–53.
   Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641–1648.
   PubMed Web of Science ®Google Scholar
• Fujino Y, Asaoka R, Murata H, et al. Evaluation of glaucoma progression in large-scale clinical data: the Japanese Archive of Multicentral Databases in Glaucoma (JAMDIG). Invest Ophthalmol Vis Sci. 2016;57(4):2012–2020.
   PubMed Web of Science ®Google Scholar
• Roberts CB, Hiratsuka Y, Yamada M, et al. Economic cost of visual impairment in Japan. Arch Ophthalmol. 2010;128(6):766–771.
   PubMedGoogle Scholar
• Japan Ophthalmologist Association. Social costs of visual impairment in Japan. Tokyo; 2009.
   Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740.
   PubMed Web of Science ®Google Scholar
• Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68–74.
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116(2):191–199.
   PubMed Web of Science ®Google Scholar
• Matlin OS, Kymes SM, Averbukh A, et al. Community pharmacy automatic refill program improves adherence to maintenance therapy and reduces wasted medication. Am J Manag Care. 2015;21(11):785–791.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kondo M, Fuchigami A, et al. Effects of implementation of glaucoma patients visit persistence support system on visit persistent rate of glaucoma patients. Ganka. 2020;62(8):801–807.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Goto R, Yoneyama-Hirozane M. Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ. 2019;22(10):1041–1046.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112(10):1661–1669.
   PubMed Web of Science ®Google Scholar
• National Institute of Population and Social Security Research. All Japan: life table data series 2020 [cited 2020 Jun 23]. Available from: http://www.ipss.go.jp/p-toukei/JMD/00/index-en.html.
   Google Scholar
• Ministry of Health, Labour and Welfare. Future outlook for social security with a view to 2040 (Discussion material) (translated from Japanese). Ministry of Health, Labour and Welfare; 2018 [cited 2020 Jun 23]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000207382.html.
   Google Scholar
• Research team (Team Leader: Takashi Fukuda) on cost-effectiveness evaluation supported by Health and Labour Science Research Grants (Strategic Integrated Scientific Research Project). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. CORE 2 HEALTH; 2019.
   Google Scholar
• Ederer F, Gaasterland DA, Dally LG, et al. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology. 2004;111(4):651–664.
   PubMed Web of Science ®Google Scholar
• Malihi M, Moura Filho ER, Hodge DO, et al. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121(1):134–141.
   PubMed Web of Science ®Google Scholar
• Newman-Casey PA, Salman M, Lee PP, et al. Cost-utility analysis of glaucoma medication adherence. Ophthalmology. 2020;127(5):589–598.
   PubMed Web of Science ®Google Scholar
• Bhartiya S, Clement C, Dorairaj S, et al. [Clinical decision making in glaucoma] (English edition). New Delhi: Jaypee Brothers Medical Publishers LTD.; 2019.
   Google Scholar
• Fukuchi T, Yoshino T, Sawada H, et al. Progression rate of total, and upper and lower visual field defects in open-angle glaucoma patients. Clin Ophthalmol. 2010;4:1315–1323.
   PubMedGoogle Scholar
• Nitta K, Wajima R, Tachibana G, et al. Prediction of visual field progression in patients with primary open-angle glaucoma, mainly including normal tension glaucoma. Sci Rep. 2017;7(1):15048.
   PubMedGoogle Scholar
• Oie S, Ishida K, Yamamoto T. Impact of intraocular pressure reduction on visual field progression in normal-tension glaucoma followed up over 15 years. Jpn J Ophthalmol. 2017;61(4):314–323.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Digiuni M, Montesano G, et al. Blindness and glaucoma: a multicenter data review from 7 academic eye clinics. PLOS One. 2015;10(8):e0136632.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56.
   PubMedGoogle Scholar
• Chang T, Ramulu P, Hodapp E. Clinical decisions in glaucoma. 2nd ed. Miami (FL): Bascom Palmer Eye Institute; 2016.
   Google Scholar
• Japan Penson Service. Requirements for receiving basic disability pensions, payment start timing, and calculation method [cited 2020 Mar 4]. Available from: https://www.nenkin.go.jp/service/jukyu/shougainenkin/jukyu-yoken/20150514.html.
   Google Scholar
• National Tax Agency. No.2260 a tax rate of an income tax [cited 2020 Apr 4]. Available from: https://www.nta.go.jp/taxes/shiraberu/taxanswer/shotoku/2260.htm.
   Google Scholar
• Rein DB, Wirth KE, Johnson CA, et al. Estimating quality-adjusted life year losses associated with visual field deficits using methodological approaches. Ophthalmic Epidemiol. 2007;14(4):258–264.
   PubMed Web of Science ®Google Scholar
• National Research Council Committee on Disability Determination for Individuals with Visual Impairments. Tests of visual functions. In: Lennie P, Van Hemel SB, editors. Visual impairments: determining eligibility for social security benefits. Washington (DC): National Academies Press; 2002. p. 51–125.
   Google Scholar
• Dowie J, Kaltoft MK, Nielsen JB, et al. Caveat emptor NICE: biased use of cost-effectiveness is inefficient and inequitable. F1000Res. 2015;4:1078.
   PubMedGoogle Scholar
• Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82(11):887–888.
   PubMed Web of Science ®Google Scholar
• Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59(Suppl1):S93–S96.
   PubMedGoogle Scholar
• Rodgers PT, Ruffin DM. Medication nonadherence: Part II – a pilot study in patients with congestive heart failure. Manag Care Interface. 1998;11(9):67–69.
   PubMedGoogle Scholar
• Lui M-H, Lam JCH, Kwong YL, et al. A cross-sectional study on compliance with topical glaucoma medication and its associated socioeconomic burden for a Chinese population. Int J Ophthalmol. 2017;10(2):293–299.
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock SJ, Carpenter DM, et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology. 2015;122(4):748–754.
   PubMed Web of Science ®Google Scholar
• Feehan M, Munger MA, Cooper DK, et al. Adherence to glaucoma medications over 12 months in two US community pharmacy chains. J Clin Med. 2016;5(9):79.
   Web of Science ®Google Scholar